Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
12 sept. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...